Howard Hochster, MD, shares opinion of the \

(5:51)

Dr. Howard Hochster Discusses Clinical Cancer, Gastrointestinal (GI) Oncology, and Colon Cancer

(2:23)

Howard Hochster, MD, Explains Colorectal Cancer Screening Guidelines

(1:34)

Dr. Howard Hochster Discusses the Importance of Clinical Trials in Oncology

(1:49)

Howard Hochster, MD, explains the role of ramucirumab in the treatment of GE junction cancers

(2:9)

Howard Hochster, MD, explains how to manage 2nd and 3rd line mCRC patients

(1:49)

Olas Ixtapa, 12 de septiembre 2014.

(52)

Self Advocate and Do Your Own Research | Howard Wolinsky’s #ProstateCancer Patient Story | PCRI

(18:40)

Congresswoman Katie Porter grills billionaire CEO over pay disparity at JP Morgan

(2:36)

NBA \

(9:11)

Top 10 Highest Vertical Jumps In NBA History

(7:49)

A Historic Day for Kiteboarding: New World Record Set in Denmark!

(1:31)

The NEW World’s Highest Basketball Shot

(17:42)

A Yiddish Hartz-Hershy Rottenberg, Freilach Band, Shira Choir|א אידיש הארץ -רוטנבערג, שירה, פריילך

(6:37)

PCRI Honors Howard Wolinsky, Active Surveillance \u0026 #ProstateCancer Advocate | Harry Pinchot Award

(15:29)

Extreme Stormy Kite Surfing Jumps

(13:31)

Howard Hochster, MD, on whether atezolizumab + bevacizumab regimen is a new standard in care in HCC

(4:23)

Howard Hochster, MD, considers patient age and the OncotypeDX recurrence score in CRC

(1:19)

Howard Hochster, MD, regarding the role of genetic testing in mCRC

(1:15)

Howard Hochster Part 1 of 3

(43)

Howard Hochster MD, provides thoughts on potential practice changing results of the Keynote177 study

(1:16)

Howard Hochster, MD, provides thoughts on the clinical progress of Enhertu in GI cancers

(2:9)

Howard Hochster, MD, on the management of mCRC patients receiving regorafenib

(1:30)

Howard Hochster, MD, outlines the results of the Checkmate 142 study in mCRC patients

(2:7)

Howard Hochster, MD talks about predictive response therapy based on site of tumor in mCRC

(1:53)

Howard S. Hochster, MD, discusses if genetic profiling has changed treating CRC patients

(3:41)

Howard Hochster, MD explains outcomes from the phase 3 CALGB/SWOG 80405 study

(2:16)

Howard Hochster, MD, considers next generation sequencing and mCRC treatment decisions

(1:25)

Howard Hochster, MD, offers opinion on the ReDOS study and dose escalation of regorafenib

(1:34)